Skip to main content
SpringerLink
Log in

Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Non-Hispanic Black patients are disproportionally affected by multiple myeloma (MM) and whether efficacy outcomes after autologous stem cell transplant (ASCT) differ by race and ethnicity remains an area of active investigation. This study included 449 patients enriched with a large proportion of non-Hispanic Black patients and sought to highlight the impact of race and ethnicity on outcomes after HDT-ASCT for patients with newly diagnosed MM. We found induction chemotherapy followed by high-dose therapy-ASCT and maintenance chemotherapy is associated with long-term PFS and OS, regardless of race or ethnicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086–1107. https://doi.org/10.1002/ajh.26590

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48

    Article  PubMed  Google Scholar 

  3. Benjamin M, Reddy S, Brawley OW (2003) Myeloma and race: a review of the literature. Cancer Metastasis Rev 22(1):87–93

    Article  PubMed  CAS  Google Scholar 

  4. Ailawadhi S, Aldoss IT, Yang D et al (2012) Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 158(1):91–98. https://doi.org/10.1111/j.1365-2141.2012.09124.x

    Article  PubMed  Google Scholar 

  5. Ailawadhi S, Jacobus S, Sexton R et al (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8(7):67. https://doi.org/10.1038/s41408-018-0102-7

    Article  PubMed  PubMed Central  Google Scholar 

  6. Peres LC, Colin-Leitzinger CM, Teng M et al (2022) Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv 6(12):3767–3778. https://doi.org/10.1182/bloodadvances.2021006652

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686. https://doi.org/10.1182/blood-2010-02-268862

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Schriber JR, Hari PN, Ahn KW et al (2017) Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer 123(16):3141–3149. https://doi.org/10.1002/cncr.30747

    Article  PubMed  CAS  Google Scholar 

  9. Perrot A, Lauwers-Cances V, Cazaubiel T et al (2020) Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood 136:Suppl 1:39–39. https://www.sciencedirect.com/science/article/pii/S0006497118693644

  10. Richardson PG, Jacobus SJ, Weller EA et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132–147

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Chng WJ, Dispenzieri A, Chim CS et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269–277. https://doi.org/10.1038/leu.2013.247

    Article  PubMed  CAS  Google Scholar 

  12. National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services. Nov. Accessed 28 January 2023. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

  13. Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548

    Article  PubMed  Google Scholar 

  14. United States Census Bureau Quickfacts: South Carolina. Accessed April 7, 2023. https://www.census.gov/quickfacts/fact/table/SC/PST045222

  15. Joseph NS, Kaufman JL, Dhodapkar MV et al (2020) Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 38(17):1928–1937. https://doi.org/10.1200/JCO.19.02515

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Fillmore NR, Yellapragada SV, Ifeorah C et al (2019) With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 133(24):2615–2618. https://doi.org/10.1182/blood.2019000406

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Dong J, Garacci Z, Buradagunta CS et al (2022) Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J 12(2):34. https://doi.org/10.1038/s41408-022-00633-5

    Article  PubMed  PubMed Central  Google Scholar 

  18. Nooka AK, Kaufman JL, Rodriguez C et al (2020) MM-350: daratumumab (Dara) + lenalidomide/bortezomib/dexamethasone (Rvd) in african american/black patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (Ndmm): subgroup analysis of griffin. Clin Lymphoma Myeloma Leuk 20:S308–S309. https://doi.org/10.1016/S2152-2650(20)30956-3

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Division of Malignant Hematology and Bone Marrow Transplant, Department of Pharmacy, Medical University of South Carolina, 86 Jonathan Lucas St, Charleston, SC, 29425, USA

    James A. Davis, Kelly J. Gaffney, Deidra Smith, Andy Maldonado & Katelynn Granger

  2. Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA

    Aswani Thurlapati, Kristy E. Martin, Yolanda M. Williams, Arash Velayati, Jonathan K. Bakos, Kimberly Green & Hamza Hashmi

  3. Medical University of South Carolina College of Pharmacy, Charleston, SC, USA

    Erin Weeda & Taylor Herrington

Authors
  1. James A. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aswani Thurlapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erin Weeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kelly J. Gaffney
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deidra Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andy Maldonado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katelynn Granger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kristy E. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yolanda M. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Taylor Herrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Arash Velayati
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jonathan K. Bakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kimberly Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hamza Hashmi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.D. and H.H. wrote the manuscript. All authors were involved in data extraction, analysis, and review of the final manuscript.

Corresponding author

Correspondence to James A. Davis.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

This study was IRB approved.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, J.A., Thurlapati, A., Weeda, E. et al. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Ann Hematol 103, 251–258 (2024). https://doi.org/10.1007/s00277-023-05503-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05503-z

Keywords

Search

Navigation